Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Cash from Investing Activities of -$8.0 million for Q1 2026, up 24.42% year-over-year from -$6.4 million in Q1 2025, and up 68.56% quarter-over-quarter from -$25.4 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$8.0 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 24.42% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$89.8 million (down 1233.16% YoY), while the FY2025 annual figure was -$92.4 million, down 2336.44% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$8.0 million, up from -$25.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $22.6 million in Q1 2022, with the low at -$33.2 million in Q3 2025.
- The 5-year median for Cash from Investing Activities is $313000.0 (2024), against an average of -$1.6 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 424.96% in 2024, then tumbled 3471.25% in 2025.
- Rigel Pharmaceuticals' Cash from Investing Activities stood at $18.6 million in 2022, then plunged by 136.96% to -$6.9 million in 2023, then slumped by 58.77% to -$10.9 million in 2024, then slumped by 132.38% to -$25.4 million in 2025, then surged by 68.56% to -$8.0 million in 2026.
- Business Quant data shows RIGL's Cash from Investing Activities at -$8.0 million in Q1 2026, -$25.4 million in Q4 2025, and -$33.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 17.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.45 Mn |
| Jun 30, 2026 | 17.45 Mn |
| Mar 31, 2026 | -7.98 Mn |
| Mar 31, 2026 | -7.98 Mn |
| Dec 31, 2025 | -25.36 Mn |
| Dec 31, 2025 | -25.36 Mn |
| Sep 30, 2025 | -33.18 Mn |
| Sep 30, 2025 | -33.18 Mn |
| Jun 30, 2025 | -23.28 Mn |
| Jun 30, 2025 | -23.28 Mn |
| Mar 31, 2025 | -10.55 Mn |
| Mar 31, 2025 | -10.55 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Mar 31, 2024 | 313,000.00 |
| Mar 31, 2024 | 313,000.00 |